<DOC>
	<DOCNO>NCT00268983</DOCNO>
	<brief_summary>Comparison rituximab versus Iodine I 131 Tositumomab Therapeutic Regimen ( Tositumomab Iodine I 131 Tositumomab Bexxar Therapeutic Regimen , formerly call Iodine-131 Anti-B1 Antibody ) subject follicular non Hodgkins B cell lymphoma . 506 subject enrol 30 40 site US , Canada , Europe . Subjects randomly assign one two treatment arm . In Arm A , subject receive 375 milligrams/meter2 ( mg/m2 ) rituximab , give intravenous ( IV ) infusion weekly 4 week . In Arm B , subject undergo two-phase treatment . In first phase , term `` dosimetric dose , '' subject receive infusion unlabeled Tositumomab ( 450 mg ) immediately follow infusion 5 millicurie ( mCi ) ( 0.18 gigabecquerel [ GBq ] ) Iodine 131 Tositumomab ( 35 mg ) . Whole body gamma camera scan obtain three time ( Day 0 ; Day 2 , 3 , 4 ; Day 6 7 ) follow dosimetric dose . The information derive scan enable patient specific dose calculate deliver desire total body dose radiation ( 65 75 centigray [ cGy ] ) . In second phase , term `` therapeutic dose , '' subject Arm B receive infusion unlabeled Tositumomab ( 450 mg ) immediately follow infusion subject specific activity Iodine 131-conjugated Tositumomab ( 35 mg ) . Thyroid blockade implement 24 hour prior dosimetric dose continue 14 day follow therapeutic dose . Subjects study follow response safety Week 7 , Week 13 , every three month first second year , every six month third year , annually forth fifth year ; vital status , additional therapy , long term safety event year ten . Follow Up subsequent NHL therapy carry assess tolerance next anti-lymphoma therapy , development myelodysplasia ( MDS ) /acute myelogenous leukemia ( AML ) , HAMA hypothyroidism , unexpected safety issue , death .</brief_summary>
	<brief_title>Comparison Of Rituximab Versus Tositumomab Iodine I 131 Tositumomab ( BEXXARÂ® Therapeutic Regimen ) For Patients With Relapsed Follicular Non-Hodgkins Lymphoma</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Lymphoma , Follicular</mesh_term>
	<mesh_term>Iodine-131 anti-B1 antibody</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<mesh_term>Iodine</mesh_term>
	<mesh_term>Cadexomer iodine</mesh_term>
	<criteria>Inclusion criterion : Histologically confirm diagnosis follicular lymphoma Recurrent lymphoma one two qualify therapy regimen ( ) Patients must progress within 4 week last chemotherapy dose Rituximab may use single agent , one continuous course 48 weekly infusion ( 10week period ) , combination chemotherapy single prior treatment Patients whose prior therapy include rituximab must 6 month great response duration follow rituximabcontaining regimen . Performance status least 70 % Karnofsky Scale anticipate survival least three month Adequate absolute neutrophil count platelet count within 21 day study entry without support blood products/growth factor Adequate renal function adequate hepatic within 21 day study entry Measurable disease , least one lesion measure &gt; /=2.0 cm x 2.0 cm CT scan Human Anti Mouse Antigen negative Written inform consent prior study entry Exclusion criterion : Histologic transformation diffuse , large cell lymphoma . History one course Rituximab Disease limit single lymph node single group nod Involvement 25 % intratrabecular marrow bone marrow biopsy specimen . Active infection require IV antibiotic time study entry New York Heart Association Class III/IV heart disease Prior chemotherapy , biologic , radiation steroid therapy NHL within 8 week Any prior radioimmunotherapy Prior history malignancy lymphoma ( except treat basal cell , squamous cell skin cancer , situ cervical cancer , cancer diseasefree 5 year ) Known HIV infection Hepatitis B positive Known central nervous system involvement</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>rituximab</keyword>
	<keyword>tositumomab iodine I 131 tositumomab</keyword>
	<keyword>non-Hodgkins lymphoma</keyword>
	<keyword>radioimmunotherapy</keyword>
	<keyword>anti-B1 antibody</keyword>
	<keyword>Bexxar</keyword>
	<keyword>NHL</keyword>
	<keyword>Tositumomab</keyword>
</DOC>